Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors
Conjupro Biotherapeutics, Inc.
Conjupro Biotherapeutics, Inc.
Centre Oscar Lambret
Luzerner Kantonsspital
Assistance Publique - HĂ´pitaux de Paris
Pfizer
Ocellaris Pharma, Inc.
NiKang Therapeutics, Inc.
Pfizer
Pfizer
NuCana plc
National Institutes of Health Clinical Center (CC)
AHS Cancer Control Alberta
Advanced Accelerator Applications
Coherus Oncology, Inc.
Icahn School of Medicine at Mount Sinai
Poseida Therapeutics, Inc.
Altor BioScience
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Medikine, Inc.
University of Virginia
Pfizer
National Cancer Institute (NCI)
Vanderbilt University Medical Center
Children's National Research Institute
Hoffmann-La Roche
4D pharma plc
West Virginia University
Duke University
Bristol-Myers Squibb
Case Comprehensive Cancer Center
Genocea Biosciences, Inc.
Universitätsklinikum Hamburg-Eppendorf
CG Oncology, Inc.
PharmaMar
KitovPharma
National Institutes of Health Clinical Center (CC)
Ottawa Hospital Research Institute
Emory University
InSightec
Kaiser Permanente
Heat Biologics
Chronix Biomedical Corporation
National Institutes of Health Clinical Center (CC)
Novartis
Eli Lilly and Company
CureOne
NYU Langone Health
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
AbbVie